THE WOODLANDS, Texas--(BUSINESS WIRE)--Nov. 11, 2005--Zonagen, Inc. (Nasdaq:ZONA)(PCX:ZONA) today reported financial results for the three-month and nine-month periods ended September 30, 2005 and provided an update on its clinical development efforts for Proellex(TM) and Androxal(TM).
